Lista de obras - Sanjay Popat - Dominio Público Uruguay

193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received ≥1 prior systemic treatment

A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer

artículo científico publicado en 2016

A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material.

artículo científico publicado en 2014

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.

artículo científico publicado en 2015

A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks ⬇️

artículo científico publicado el 24 de noviembre de 2011

A pilot study of a novel home telemonitoring system for oncology patients receiving chemotherapy.

artículo científico publicado en 2013

A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings

artículo científico publicado en 2010

A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer

article

A randomised assessment of the use of a quality of life questionnaire with or without intervention in patients attending a thoracic cancer clinic

artículo científico publicado en 2015

A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma

artículo científico publicado en 2016

A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations.

artículo científico publicado en 2013

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice

artículo científico publicado en 2014

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

artículo científico publicado en 2017

A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis

artículo científico publicado en 2005

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

artículo científico publicado en 2014

ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.

artículo científico publicado en 2011

Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.

artículo científico publicado en 2017

Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.

artículo científico publicado en 2017

Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.

artículo científico publicado en 2014

Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.

artículo científico publicado en 2014

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

artículo científico publicado en 2015

Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.

artículo científico

Allelic imbalance in colorectal cancer at the CRAC1 locus in early-onset colorectal cancer

artículo científico publicado en 2003

An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.

artículo científico publicado en 2017

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity.

artículo científico publicado en 2014

Analysis of the CTLA4 gene in Swedish coeliac disease patients

article

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

artículo científico publicado en 2014

Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies

artículo científico publicado en 2016

COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss ⬇️

artículo científico publicado en 2017

Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.

artículo científico publicado en 2016

Chemotherapy strategies in the treatment of small cell lung cancer.

artículo científico publicado en 2005

Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report

artículo científico publicado en 2011

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

artículo científico publicado en 2017

Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.

artículo científico

Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC

artículo científico publicado en 2014

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.

artículo científico publicado en 2016

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients

artículo científico publicado en 2016

Development of molecularly targeted agents and immunotherapies in small cell lung cancer.

artículo científico publicado en 2016

Do Statins Improve Survival in Small-Cell Lung Cancer?

artículo científico publicado en 2017

EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib

artículo científico publicado en 2020

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

artículo científico publicado en 2013

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma

artículo científico publicado en 2013

Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival

artículo científico publicado en 2007

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach

artículo científico publicado en 2015

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

artículo científico publicado en 2017

Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.

artículo científico publicado en 2007

Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors

artículo científico publicado en 2011

Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer.

artículo científico publicado en 2016

Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations ⬇️

artículo científico publicado el 14 de octubre de 2011

Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome

artículo científico publicado en 2005

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.

artículo científico publicado en 2016

First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is….

artículo científico publicado en 2016

Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice

artículo científico publicado en 2015

Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence

artículo científico publicado en 2006

Genome screening of coeliac disease.

artículo científico publicado en 2002

Good vibrations and the power of positron thinking: positron emission tomography and endoscopic ultrasound in staging of mesothelioma-two case reports.

artículo científico publicado en 2008

Guidelines on the radical management of patients with lung cancer

scientific article published on 01 October 2010

Gut microflora associated characteristics in first-degree relatives of children with celiac disease

artículo científico publicado en 2007

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

scientific article published on 13 May 2016

Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985-2010.

artículo científico publicado en 2011

Hyperprogression with immunotherapy: Is it real?

artículo científico publicado en 2019

In Reply:

Influence of co-morbidity on renal function assessment by Cockcroft-Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy.

artículo científico publicado en 2011

Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance

artículo científico publicado en 2006

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma

artículo científico publicado en 2017

Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia

artículo científico publicado en 1999

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib

artículo científico publicado en 2011

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).

artículo científico publicado en 2015

Malignant pleural mesothelioma: two cases in first degree relatives.

artículo científico publicado en 2007

Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

artículo científico

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer.

artículo científico publicado en 2016

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

artículo científico publicado en 2014

Mismatch repair, minichromosome maintenance complex component 2, cyclin A, and transforming growth factor β receptor type II as prognostic factors for colorectal cancer: results of a 10-year prospective study using tissue microarray analysis.

artículo científico publicado en 2011

Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience

artículo científico publicado en 2017

Mutational analysis of CD28 in coeliac disease.

artículo científico publicado en 2002

Navigating diagnostic and treatment decisions in non-small-cell lung cancer: expert commentary on the multidisciplinary team approach

artículo científico publicado en 2020

Never smoker with ground glass opacities on CT

artículo científico publicado en 2015

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

artículo científico publicado en 2017

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options

artículo científico publicado en 2017

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer: a network meta-analysis

artículo científico publicado en 2014

Novel insights into mesothelioma biology and implications for therapy.

artículo científico publicado en 2017

Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer.

artículo científico publicado en 2018

Palliative treatments for patients with inoperable gastroesophageal cancers

artículo científico publicado en 2006

Patient factors, health care factors and survival from lung cancer according to ethnic group in the south of London, UK.

artículo científico publicado en 2012

Patient reported outcomes from LUX-Lung 3: first-line afatinib is superior to chemotherapy-would patients agree?

artículo científico

Patterns of relapse in extrapulmonary small cell carcinoma: retrospective analysis of outcomes from two cancer centres

artículo científico publicado en 2015

Phase 2 study of sorafenib in malignant mesothelioma previously treated with platinum-containing chemotherapy.

artículo científico publicado en 2013

Phase I clinical trials in patients with advanced non-small cell lung cancer treated within a Drug Development Unit: What have we learnt?

artículo científico publicado en 2017

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Trea

artículo científico publicado en 2013

Platinum-based chemotherapy in triple-negative breast cancer.

artículo científico publicado en 2008

Polymorphic sequence variants in medicine: a challenge and an opportunity.

artículo científico publicado en 2003

Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer.

artículo científico publicado en 2017

Prevalence of the APC E1317Q variant in colorectal cancer patients

artículo científico publicado en 2000

Problems of variable biomarker evaluation in stratified medicine research--A case study of ERCC1 in non-small-cell lung cancer

artículo científico publicado en 2016

Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer

artículo científico publicado en 2014

Randomized, phase III trial of figitumumab in combination with erlotinib versus erlotinib alone in patients with nonadenocarcinoma nonsmall-cell lung cancer

artículo científico publicado en 2014

Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung.

artículo científico

Re: Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis

scientific article published on 01 June 2005

Re: Reporting Recommendations for Tumor Marker Prognostic Studies (REMARK)

artículo científico publicado en 2005

Refining the diagnosis and EGFR status of non-small cell lung carcinoma in biopsy and cytologic material, using a panel of mucin staining, TTF-1, cytokeratin 5/6, and P63, and EGFR mutation analysis.

artículo científico publicado en 2010

Relationship between chromosome 18q status and colorectal cancer prognosis: a prospective, blinded analysis of 280 patients

artículo científico publicado en 2007

Relationship between thymidylate synthase (TS) genotype and TS expression: a tissue microarray analysis of colorectal cancers

artículo científico publicado en 2005

Resolution of severe hyponatraemia is associated with improved survival in patients with cancer

artículo científico publicado en 2015

Response evaluation in mesothelioma: Beyond RECIST.

artículo científico

Risk of non-medullary thyroid cancer influenced by polymorphic variation in the thyroglobulin gene

artículo científico publicado en 2003

Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data

artículo científico publicado en 2014

Small-cell lung cancer (SCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

artículo científico publicado en 2013

Sunitinib (SU11248) in patients with chemo naive extensive small cell lung cancer or who have a 'chemosensitive' relapse: A single-arm phase II study (EORTC-08061).

artículo científico publicado en 2015

Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.

artículo científico publicado en 2010

Symptom and Quality of Life Improvement in LUX-Lung 8, an Open-Label Phase III Study of Second-Line Afatinib Versus Erlotinib in Patients With Advanced Squamous Cell Carcinoma of the Lung After First-Line Platinum-Based Chemotherapy

artículo científico

Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients ⬇️

artículo científico publicado el 12 de abril de 2013

Systematic review of microsatellite instability and colorectal cancer prognosis

artículo científico publicado en 2005

Systemic therapy for pulmonary carcinoids.

artículo científico

Tailoring Microbial Electrochemical Cells for Production of Hydrogen Peroxide at High Concentrations and Efficiencies.

artículo científico publicado en 2016

Targeting MET Exon 14 Skipping Alterations: Has Lung Cancer MET Its Match?

artículo científico publicado en 2017

The National Lung Matrix Trial of personalized therapy in lung cancer

artículo científico publicado en 2020

The National Lung Matrix Trial: translating the biology of stratification in advanced non-small-cell lung cancer

artículo científico publicado en 2015

The combination of Young's syndrome and small cell lung cancer-A spiky connection?

artículo científico publicado en 2009

The efficacy of crizotinib in patients with ALK-positive nonsmall cell lung cancer.

artículo científico

The value of day 8 blood count in treatment decisions when using oral vinorelbine in non-small cell lung cancer.

artículo científico publicado en 2010

Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis

artículo científico publicado en 2004

Time and chemotherapy treatment trends in the treatment of elderly patients (age >/=70 years) with small cell lung cancer.

artículo científico publicado en 2006

Time and chemotherapy treatment trends in the treatment of elderly patients (age>or=70 years) with non-small cell lung cancer

artículo científico publicado en 2008

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer.

artículo científico publicado en 2014

Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.

artículo científico publicado en 2013

Transformation to neuroendocrine carcinoma as a resistance mechanism to lorlatinib

artículo científico publicado en 2019

Treatment choice in epidermal growth factor receptor mutation-positive non-small cell lung carcinoma: latest evidence and clinical implications.

artículo científico publicado en 2017

Treatment options for small cell lung cancer - do we have more choice?

artículo científico publicado en 2010

Treatments for EGFR Mutation-Positive (M+) NSCLC Patients - A Network Meta-Analysis (NMA) by Mutation Type

scientific article published on 26 October 2014

True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancer

artículo científico publicado en 2011

Under usage of zoledronic acid in non-small cell lung cancer patients with metastatic bone disease – a short communication ⬇️

artículo científico publicado el 16 de junio de 2011

Watch the weathercock: changes in re-staging 18F-FDG PET/CT scan predict the probability of relapse in locally advanced non-small cell lung cancer.

artículo científico publicado en 2015

What exactly are we doing to improve low lung cancer survival in the United Kingdom?

artículo científico publicado en 2013

Lista de obras de Sanjay Popat

193TiP: CheckMate 171: A multicenter phase 2 trial of nivolumab (nivo) in patients (pts) with stage IIIB/IV squamous cell (SQ) NSCLC who have received ≥1 prior systemic treatment

A Validation Study for the Use of ROS1 Immunohistochemical Staining in Screening for ROS1 Translocations in Lung Cancer

A comparison of immunohistochemical assays and FISH in detecting the ALK translocation in diagnostic histological and cytological lung tumor material.

A phase 1b trial of the combination of an all-oral regimen of capecitabine and erlotinib in advanced non-small cell lung cancer in Caucasian patients.

A phase II study of 18F-fluorodeoxyglucose PET–CT in non-small cell lung cancer patients receiving erlotinib (Tarceva®); objective and symptomatic responses at 6 and 12weeks ⬇️

A pilot study of a novel home telemonitoring system for oncology patients receiving chemotherapy.

A prospective study of chemotherapy-induced febrile neutropenia in the South West London Cancer Network. Interpretation of study results in light of NCAG/NCEPOD findings

A prospective, blinded analysis of thymidylate synthase and p53 expression as prognostic markers in the adjuvant treatment of colorectal cancer

A randomised assessment of the use of a quality of life questionnaire with or without intervention in patients attending a thoracic cancer clinic

A randomised study comparing the effectiveness of acupuncture or morphine versus the combination for the relief of dyspnoea in patients with advanced non-small cell lung cancer and mesothelioma

A rare case of squamous cell carcinoma of the lung harbouring ALK and BRAF activating mutations.

A serum mesothelin level is a prognostic indicator for patients with malignant mesothelioma in routine clinical practice

A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments

A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis

AKT inhibition synergistically enhances growth-inhibitory effects of gefitinib and increases apoptosis in non-small cell lung cancer cell lines

ALK translocation is associated with ALK immunoreactivity and extensive signet-ring morphology in primary lung adenocarcinoma.

Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer.

Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer.

Afatinib in the treatment of EGFR mutation-positive NSCLC--a network meta-analysis.

Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: the United Kingdom Named Patient Programme.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.

Allelic imbalance in colorectal cancer at the CRAC1 locus in early-onset colorectal cancer

An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach.

An unblinded, randomised phase II study of platinum-based chemotherapy with vitamin B12 and folic acid supplementation in the treatment of lung cancer with plasma homocysteine blood levels as a biomarker of severe neutropenic toxicity.

Analysis of the CTLA4 gene in Swedish coeliac disease patients

Assessing standardization of molecular testing for non-small-cell lung cancer: results of a worldwide external quality assessment (EQA) scheme for EGFR mutation testing

Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies

COAST (Cisplatin ototoxicity attenuated by aspirin trial): A phase II double-blind, randomised controlled trial to establish if aspirin reduces cisplatin induced hearing-loss ⬇️

Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions.

Chemotherapy strategies in the treatment of small cell lung cancer.

Chemotherapy-induced bowel obstruction in small cell lung cancer: a case report

Clinical outcomes and prognostic factors of patients with advanced mesothelioma treated in a phase I clinical trials unit.

Closing faucets: the role of anti-angiogenic therapies in malignant pleural diseases.

Combining targeted agents and hypo- and hyper-fractionated radiotherapy in NSCLC

Continuing EGFR inhibition beyond progression in advanced non-small cell lung cancer.

Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients

Development of molecularly targeted agents and immunotherapies in small cell lung cancer.

Do Statins Improve Survival in Small-Cell Lung Cancer?

EGFR Exon 20 Insertion (A763_Y764insFQEA) Mutant NSCLC Is Not Identified by Roche Cobas Version 2 Tissue Testing but Has Durable Intracranial and Extracranial Response to Osimertinib

EGFR and KRAS mutations, and ALK fusions: current developments and personalized therapies for patients with advanced non-small-cell lung cancer.

Early pneumothorax as a feature of response to crizotinib therapy in a patient with ALK rearranged lung adenocarcinoma

Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival

Efficient Genotyping of KRAS Mutant Non-Small Cell Lung Cancer Using a Multiplexed Droplet Digital PCR Approach

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Erlotinib, docetaxel, and gefitinib in sequential cohorts with relapsed non-small cell lung cancer.

Establishing an EGFR mutation screening service for non-small cell lung cancer - sample quality criteria and candidate histological predictors

Eventual role of EGFR-tyrosine kinase inhibitors in early-stage non-small-cell lung cancer.

Excision Repair Cross-Complementation Group 1 (ERCC1) Status and Lung Cancer Outcomes: A Meta-Analysis of Published Studies and Recommendations ⬇️

Exon 3 beta-catenin mutations are specifically associated with colorectal carcinomas in hereditary non-polyposis colorectal cancer syndrome

First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases.

First-line Epidermal Growth Factor Receptor (EGFR) Kinase Inhibitors for EGFR Mutant Non-small Cell Lung Cancer: And the Winner is….

Focused molecular analysis of small cell lung cancer: feasibility in routine clinical practice

Genetic variants of UGT1A6 influence risk of colorectal adenoma recurrence

Genome screening of coeliac disease.

Good vibrations and the power of positron thinking: positron emission tomography and endoscopic ultrasound in staging of mesothelioma-two case reports.

Guidelines on the radical management of patients with lung cancer

Gut microflora associated characteristics in first-degree relatives of children with celiac disease

High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial

Human papillomavirus types 16 and 18 in epithelial dysplasia of oral cavity and oropharynx: a meta-analysis, 1985-2010.

Hyperprogression with immunotherapy: Is it real?

In Reply:

Influence of co-morbidity on renal function assessment by Cockcroft-Gault calculation in lung cancer and mesothelioma patients receiving platinum-based chemotherapy.

Inter-relationship between microsatellite instability, thymidylate synthase expression, and p53 status in colorectal cancer: implications for chemoresistance

LUME-Meso: Design and Rationale of the Phase III Part of a Placebo-Controlled Study of Nintedanib and Pemetrexed/Cisplatin Followed by Maintenance Nintedanib in Patients With Unresectable Malignant Pleural Mesothelioma

Linkage analysis for ATM in familial B cell chronic lymphocytic leukaemia

Lung adenocarcinoma with concurrent exon 19 EGFR mutation and ALK rearrangement responding to erlotinib

Maintenance pazopanib versus placebo in Non-Small Cell Lung Cancer patients non-progressive after first line chemotherapy: A double blind randomised phase III study of the lung cancer group, EORTC 08092 (EudraCT: 2010-018566-23, NCT01208064).

Malignant pleural mesothelioma: two cases in first degree relatives.

Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.

Mechanism and non-mechanism based imaging biomarkers for assessing biological response to treatment in non-small cell lung cancer.

Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Mismatch repair, minichromosome maintenance complex component 2, cyclin A, and transforming growth factor β receptor type II as prognostic factors for colorectal cancer: results of a 10-year prospective study using tissue microarray analysis.

Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non-Small Cell Lung Cancer: A Single-Center Experience

Mutational analysis of CD28 in coeliac disease.

Navigating diagnostic and treatment decisions in non-small-cell lung cancer: expert commentary on the multidisciplinary team approach

Never smoker with ground glass opacities on CT

Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial.

Nintedanib plus docetaxel as second-line therapy in patients with non-small-cell lung cancer of adenocarcinoma histology: a network meta-analysis vs new therapeutic options